Carlsberg Signs Bottling Deal With PepsiCo in Kazakhstan and Kyrgyzstan
By Dominic Chopping
Carlsberg and PepsiCo are expanding their strategic partnership that will see the Danish brewer become the U.S. beverage company's bottler in Kazakhstan and Kyrgyzstan from Jan. 1, 2026.
The companies have agreed to cooperate in the production, sale and distribution of non-alcoholic beverages, with Carlsberg taking over the PepsiCo franchise to produce non-alcoholic beverages in the two countries.
Carlsberg said it plans to invest more than 100 million euros ($110.1 million) in building a new production facility for soft drinks in Kazakhstan, which should deliver a double-digit return on invested capital from year one and will be accretive to group return on invested capital by year three.
Carlsberg and PepsiCo already have existing bottling agreements in Norway, Sweden, Switzerland, Cambodia and Laos. Earlier this year, Carlsberg agreed to buy London-listed soft drinks maker Britvic, which, upon completion, would allow Carlsberg to produce and distribute soft drinks for PepsiCo in the U.K. and Ireland.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
September 12, 2024 05:13 ET (09:13 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks